PF-04620110 is an orally active, selective and potent DGAT1 (Acyl-CoA:diacylglycerol acyltransferase 1) inhibitor that inhibits triacylglycerol synthesis in cells and in rodents.
PF-04620110 is known to regulate gut hormones.
[1] Inhibition of DGAT1 might serve as a good approach for the treatment of obesity and type 2 diabetes.
[2] DGAT1 inhibition might increase the oxidation of fatty acids, thus it is found to be protective against hepatic steatosis.
[3]